BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $27,275.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00. Following the sale, the insider now directly owns 58,816 shares of the company’s stock, valued at approximately $1,470,400. This represents a 1.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $25.00 on Friday. The firm has a market cap of $1.18 billion, a PE ratio of -23.58 and a beta of 2.04. The firm has a fifty day moving average of $26.59 and a 200 day moving average of $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the company posted ($0.21) EPS. As a group, research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently bought and sold shares of the stock. D.A. Davidson & CO. increased its stake in shares of BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after buying an additional 519 shares during the period. Stifel Financial Corp increased its stake in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares during the period. 1620 Investment Advisors Inc. increased its stake in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of BioLife Solutions during the fourth quarter worth approximately $26,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. HC Wainwright increased their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Northland Securities raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.